Drug Profile


Alternative Names: ASL 601; N-Acetylprocainamide

Latest Information Update: 13 Jul 1999

Price : $50

At a glance

  • Originator King Pharmaceuticals Research and Development; Pfizer
  • Class Benzamides; Class III antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 13 Jul 1999 Discontinued-III for Arrhythmias in USA (IV)
  • 01 Jul 1998 Phase-III clinical trials for Arrhythmias in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top